Medicare Enrolled

Dr. Gregory Delorenzo, MD

Rheumatology · Cincinnati, OH
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Speaking/Promotional
2001 ANDERSON FERRY RD, Cincinnati, OH 45238
5139221200
In practice since 2006 (20 years)
NPI: 1508812538 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Delorenzo from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Delorenzo? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Delorenzo

Dr. Gregory Delorenzo is a rheumatology specialist in Cincinnati, OH, with 20 years of NPI registration. Based on federal Medicare data, Dr. Delorenzo performed 23,404 Medicare services across 945 unique beneficiaries.

Between the years covered by Open Payments, Dr. Delorenzo received a total of $1,294,659 from 46 pharmaceutical and/or device companies across 3647 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Delorenzo is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice ▲ Top 18% volume in OH $1,294,659 industry payments

Medicare Practice Summary

Medicare Utilization ↗
23,404
Medicare services
Top 18% in OH for rheumatology
945
Unique beneficiaries
$16
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~1,170 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Golimumab infusion (Simponi Aria)
Administration of golimumab medication directly into a vein. This code specifies the dosage amount of 1 milligram for intravenous delivery.
11,653 $10 $60
Denosumab injection (Prolia/Xgeva) 9,901 $18 $49
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
751 $75 $235
Blood draw (venipuncture)
Insertion of a needle into a vein to collect a blood sample.
342 $8 $12
Drug injection, under skin or into muscle
A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle.
286 $10 $56
Normal saline infusion, 250 cc
Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid.
139 $0 $6
Intravenous infusion, 1 hour or less
Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less.
108 $41 $163
Steroid injection (triamcinolone)
A 10 mg injection of triamcinolone acetonide, a corticosteroid medication. This code specifies the drug and dosage administered.
84 $1 $5
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
40 $91 $361
Joint injection, major joint
Removal of fluid from a large joint and/or injection of medication into the joint space.
31 $48 $333
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
29 $55 $158
X-ray of hand, 2 views
An X-ray imaging test of the hand using two different angles to visualize the bones and joints.
26 $12 $55
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
14 $115 $317
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
50.8% high complexity
44.0% medium
5.1% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$1,294,659
Total received (2018-2024)
Avg $184,951/year across 7 years
Top 1% in OH for rheumatology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
46
Companies
3,647
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$1,213,196 (93.7%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$73,292 (5.7%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$8,170 (0.6%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$157,602
2023
$206,514
2022
$169,532
2021
$86,442
2020
$101,709
2019
$283,297
2018
$289,563

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
ABBVIE INC.
$76,226
Janssen Biotech, Inc.
$39,505
GENZYME CORPORATION
$18,177
UCB, Inc.
$15,917
Amgen Inc.
$6,235
AstraZeneca Pharmaceuticals LP
$355
Novartis Pharmaceuticals Corporation
$346
Lilly USA, LLC
$258
E.R. Squibb & Sons, L.L.C.
$164
Alexion Pharmaceuticals, Inc.
$156
PFIZER INC.
$63
Radius Health, Inc.
$50
Organon Llc
$50
GlaxoSmithKline, LLC.
$29
Celgene Corporation
$24
Fresenius Kabi USA, LLC
$19
SCILEX PHARMACEUTICALS INC.
$15
SOBI, INC
$15
Top 3 companies account for 85.0% of 2024 payments
All-time payments by company (2018-2024) ›
Lilly USA, LLC
$265,127
Janssen Scientific Affairs, LLC
$204,118
ABBVIE INC.
$132,816
AbbVie Inc.
$121,275
Janssen Biotech, Inc.
$95,551
Novartis Pharmaceuticals Corporation
$93,053
Amgen Inc.
$83,307
Regeneron Healthcare Solutions, Inc.
$67,780
AbbVie, Inc.
$59,145
Celgene Corporation
$55,841
GENZYME CORPORATION
$29,514
UCB, Inc.
$27,844
E.R. Squibb & Sons, L.L.C.
$27,047
Ironwood Pharmaceuticals, Inc
$8,194
PFIZER INC.
$7,066
Mallinckrodt LLC
$6,987
Horizon Therapeutics plc
$2,427
Eli Lilly and Company
$2,300
Fresenius Kabi USA, LLC
$1,390
AstraZeneca Pharmaceuticals LP
$1,082
Mallinckrodt Hospital Products Inc.
$410
Alexion Pharmaceuticals, Inc.
$331
Genentech USA, Inc.
$322
GlaxoSmithKline, LLC.
$302
Radius Health, Inc.
$204
Exeltis, USA Inc.
$178
Horizon Pharma plc
$176
SANOFI-AVENTIS U.S. LLC
$172
Hikma Pharmaceuticals USA
$172
Johnson & Johnson Health Care Systems Inc.
$120
Takeda Pharmaceuticals U.S.A., Inc.
$65
Organon Llc
$50
MEDEXUS PHARMA, INC.
$48
Sandoz Inc.
$30
Biocon Biologics Inc
$27
ANI Pharmaceuticals, Inc.
$24
Organon LLC
$22
Mylan Institutional Inc.
$21
Oxford Immunotec USA Inc
$20
Sebela Pharmaceuticals Inc.
$16
SCILEX PHARMACEUTICALS INC.
$15
SOBI, INC
$15
MEDAC PHARMA, INC.
$15
Boehringer Ingelheim Pharmaceuticals, Inc.
$15
Flexion Therapeutics, Inc.
$13
Merck Sharp & Dohme Corporation
$13
Top 3 companies account for 46.5% of all-time payments
Associated products mentioned in payments ›
ACTHAR · AMJEVITA · AVSOLA · Actemra · BENLYSTA · Bimzelx · COSENTYX · Cimzia · DUZALLO · EVENITY · Enbrel · FORTEO · GLOPERBA · HADLIMA · HUMIRA · HYRIMOZ · Hulio · Humira · IDACIO · INFLECTRA · KEVZARA · KEVZARA SARILUMAB INJECTION · KINERET · KRYSTEXXA · Mitigare · NO PRODUCT DISCUSSED · NUCALA · OFEV · OLUMIANT · ORENCIA · Otezla · PURIFIED CORTROPHIN GEL · Prolia · RAYOS · REMICADE · RENFLEXIS · RIDAURA · RINVOQ · Rasuvo · Rinvoq · Rituxan · SAPHNELO · SIMPONI ARIA · SKYRIZI · STELARA · STRENSIQ · T-SPOT.TB8 · TALTZ · TAVNEOS · TREMFYA · Tavneos · Tymlos · Uloric · VRAYLAR · XELJANZ · Zilretta
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (94%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in rheumatology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 1% for rheumatology in OH.

Looking for a rheumatology specialist in Cincinnati?
Compare rheumatologists in the Cincinnati area by procedure volume, costs, and industry payment transparency.
Browse rheumatologists nearby

Geographic Context

Rheumatologists within 10 mi
33
Per 100K population
4.0
County median income
$70,816
Nearest hospital
MERCY HEALTH - WEST HOSPITAL
3.5 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Delorenzo is a mixed practice specialist, with above-average Medicare volume (top 18% in OH), with speaking/promotional industry engagement in the top 1% of OH peers, with 20 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Delorenzo experienced with golimumab infusion (simponi aria)?
Based on Medicare claims data, Dr. Delorenzo performed 11,653 golimumab infusion (simponi aria) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Delorenzo receive payments from pharmaceutical companies?
Yes. Dr. Delorenzo received a total of $1,294,659 from 46 companies across 3,647 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Delorenzo's costs compare to other rheumatologists in Cincinnati?
Dr. Delorenzo's average Medicare payment per service is $16. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Delorenzo) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →